Avera Research Institute, Sioux Falls, SD, Minneapolis District An FDA inspection covering three separate clinical study protocols conducted by Edward Zawada, M.
The practice is affiliated with national Clinical Study protocol groups, CALGB, (Cancer and Leukemia Group B), and NSABP (National Surgical Adjuvant Breast and Bowel Project), offering patients the opportunity of national clinical studies, through The Vermont Regional Cancer Center.
Technology, Patents, New Products Multi-layer tablet compression Enteric Coating Granulation Powder Fill (Jars, Bottles, Pouches) Micro Encapsulation Time-Release Flavor Matching Major Markets Weight Loss Supplements Multi-Nutrient Supplementation Functional Foods Nutritional Beverage Powders Major Products Tablets (Multi-layer, effervescent, chewable, dissolvable) Capsules (2 piece hard shell) Powders (Meal replacements, effervescent) Specialized Services International Regulatory Assistance Flavoring Specialists R & D Pilot Program Product Formulations Clinical Study Protocols Package and label consultation Global Capabilities Products Shipped in Over 30 Countries For International Regulatory Assistance contact: Kalpesh Bodar, E-mail kbodar@nutramedinc.
The practice is affiliated with national Clinical Study protocol groups, CALGB,(Cancer and Leukemia Group B), and NSABP(National Surgical Adjuvant Breast and Bowel Project), offering patients the opportunity of national clinical studies, through The Vermont Regional Cancer Center.
The SPA process allows for FDA evaluation of a clinical study protocol intended to form the primary basis of an efficacy claim in support of an NDA, and provides an agreement that the study design, including study size, clinical endpoints and/or data analyses are acceptable to the FDA.
Following a preliminary meeting with the FDA and through consultations with its Clinical Advisory Board, Opexa has designed a Phase I clinical study protocol.
Under the clinical study protocol, ArteFill will be injected sub-dermally over the entire metatarsal area, and patients will return at bi-weekly intervals to document level of pain, level of activity and work and recreational activities.
This Fast Track designation does not assure the approval of any of Neurologix's clinical study protocols or the ultimate approval of any Biologics License Application that the company may submit for marketing approval.
